Surface Topographies of Glaucoma Drainage Devices and Their Influence on Human Tenon Fibroblast Adhesion

Lars Choritz,1 Kaloian Koynov,2 Giulia Renieri,1 Keith Barton,3 Norbert Pfeiffer,1 and Hagen Thieme1

PURPOSE. This study was performed to investigate the surface topography of different glaucoma drainage devices and to determine the effects of surface roughness on cell adhesion of cultured human tenon fibroblasts.

METHODS. The surface topography of four widely used devices (Ahmed FP7 and Ahmed S-2; New World Medical, Inc., Rancho Cucamonga, CA; Baerveldt BG101-350; Advanced Medical Optics, Irvine, CA; and Molteno S1; Molteno Ophthalmic Ltd., Dunedin, New Zealand) was investigated by scanning electron microscopy, and roughness was quantified by white-light confocal microscopy. Cells were grown for 72 hours on the surfaces of implants affixed to standard culture dishes. The cells were labeled with a fluorescent dye and detected by confocal laser scanning microscopy, while simultaneously imaging the surface reflectance. Collagen adsorption was quantified immuno- logically by using fluorescent beads coupled to a secondary antibody.

RESULTS. The root-mean-square roughness was 1.5 ± 0.1 μm (mean ± SE) for the silicone Ahmed model FP7 and 1.3 ± 0.1 μm for the Ahmed with polypropylene base plate Ahmed model S-2. The Baerveldt was substantially smoother, with a mean roughness of 0.1 ± 0.01 μm. The Molteno was the smoothest of all devices (0.07 ± 0.01 μm). Cell adhesion was most prevalent on base plates with higher surface roughness, markedly less pronounced on the smoother base plates, and independent of collagen adsorption.

CONCLUSIONS. The most frequently implanted glaucoma drainage devices are of markedly different surface topography. Surface roughness appears to correlate with tenon fibroblast adhesion independent of collagen adsorption. Smoother base plate encapsulation. Surface roughness may thus play a role in tenon fibroblast adhesion. Further investigations are necessary to evaluate the direct correlation between surface topography and fibroblast adhesion, as well as the influence of surface chemistry on cell behavior.

Glaucoma drainage devices (GDDs) have become widely accepted in the surgical treatment of glaucoma. Although most surgeons favor their use in complicated cases, in which conventional surgical procedures such as trabeculectomy have failed, there has been some recent interest in their use as a primary surgical intervention for glaucoma.1,2 Often the long-term success of these devices is limited by failure to control IOP because of fibrous encapsulation of the implant base plate, similar to the encapsulation that is seen after other filtering procedures.3,4 In contrast to their effect in trabeculectomy, antiproliferative substances like mitomycin C or 5-fluorouracil fail to improve the long-term success of GDDs.5,6 Encapsulation, especially in pediatric patients, can lead to early failure of the implant, sometimes requiring surgical removal of the capsule or even explantation of the device.7,8

The stimuli for bleb fibrosis are not fully understood. In addition to patient-related factors such as aqueous humor TGF-β2,9 TGF-β receptor expression in tenon fibroblasts10 and previous failed ocular surgical procedures,11 several implant-related factors are probably important. Among these, the choice of biomaterial is believed to influence the initial inflammatory response to the implant,12 whereas shape, size, and rigidity of the base plate are thought to influence fibroblast growth and extracellular matrix (ECM) deposition through mechanically induced activation of the cells.13–15

One aspect of implant design that has been largely ignored is the surface texture of the base plate. Since the surface constitutes the major site of interaction with the surrounding tissue, topographic features as well as surface chemistry may well influence wound healing and the fibrotic response. This study was performed to investigate the surface texture of four commonly used GDDs and their effect on cell adhesion and growth of human tenon fibroblasts.

METHODS

Drainage Devices

Four different GDDs from three different manufacturers were used in the study. These included the Ahmed Glaucoma Valve (AGV) models FP7 (with a silicone base plate) and S-2 (the older model with a polypropylene base plate; New World Medical, Inc., Rancho Cucamonga, CA), the Baerveldt Glaucoma Implant (BGI) model BG101-350 (silicone; Advanced Medical Optics, Irvine, CA), and the Molteno Drainage Implant (MDI) single-plate model S1 (polypropylene; Molteno Ophthalmic, Ltd., Dunedin, New Zealand; Fig. 1). All devices were purchased from regular distributors and kept sterile until use.

Human Tenon Fibroblast Cell Culture

Small samples of approximately 1 to 2 mm3 of Tenon’s capsule were obtained during routine cataract or glaucoma surgery from donors who had given prior written consent. The samples were transferred to a
standard 60-mm cell culture dish, covered with a 20-mm glass cover-slip, supplied with culture medium (Dulbecco’s modified Eagle’s medium [DMEM] supplemented with 10% fetal calf serum [FCS] and 1% penicillin/streptomycin), and placed in a 37°C, 5% CO₂-containing incubator. After 1 to 2 weeks, when the cells had grown out approximately 1.5 cm from the tissue sample, they were passaged into 25-cm² culture flasks by using the trypsin/EDTA method. This passage was considered the first. All further passages were treated with the same method, with the cells being divided into three equal fractions each time. Seven individual cell lines were established in this fashion, dubbed HTF-1 to -7, three of which (HTF-1, -3, and -7, randomly chosen) were used for the cell experiments in this study. Cell identity was confirmed by immunocytochemical staining for Thy-1 with the monoclonal antibody AS02 (Dianova, Hamburg, Germany; data not shown). Cells from the fourth passage were used in the study. Tissue procurement and all experiments adhered strictly to the Declaration of Helsinki.

Scanning Electron Microscopy

Surface images of base plates (both top and bottom sides); silicone tubes; and, where applicable, the valve mechanism, were obtained by scanning electron microscopy (SEM; Gemini 1530 microscope; Carl Zeiss Meditec AG, Oberkochen, Germany; or a Nova 600 Nanolab Dualbeam system; FEI Company, Eindhoven, The Netherlands).

Profilometry by White-Light Confocal Microscopy

Representative surface areas from the base plates of all devices were scanned by 3-D white-light confocal microscopy (μSurf; NanoFocus AG, Oberhausen, Germany). Using the system software, we measured the surface profile along a randomly chosen line through each scanned section. For topographic comparison, we used the root mean square (RMS) as a basic standard parameter of surface roughness (Fig. 2).

Cell Attachment on Implant Surfaces Determined by Confocal Laser Scanning Microscopy (CLSM)

To compare the ability of human tenon fibroblasts to adhere to the native implant surfaces of the four chosen devices, we affixed the base plate of each device to a standard cell culture dish with a small amount of a clear two-component silicone (Elastosil RT 604; Wacker Chemie, Burghausen, Germany). An equal number of fourth-passage tenon fibroblasts from primary human cultures (~10⁴ cells per dish) were seeded onto the base plates and allowed to grow for 72 hours in DMEM, supplemented with 10% FCS, 1% penicillin/streptomycin at 37°C in a 5% CO₂-containing incubator. After 72 hours, the medium was discarded, and the cells were gently rinsed with PBS and stained (Cell Tracker Green CMFDA; Molecular Probes, Invitrogen, Carlsbad, CA) for 30 minutes, according to the manufacturer’s instructions. Excess dye was washed off with PBS, the culture medium was replaced and the culture dishes were reincubated for 8 hours.

Images of the cells on the upper surface of each base plate were obtained (SP2 confocal laser scanning microscope; Leica, Wetzlar, Germany). With simultaneous measurements of the fluorescence of the cell tracker dye (excitation wavelength, 488 nm by argon-ion laser) and the reflectance of a helium-neon laser (632.8 nm) from the surface, it was possible to image the cells and the surface at the same time (Fig. 3). Because of the macroscopic curvature of the base plates used in this study, it was necessary to combine series of images from up to 50 focal planes at the same position to display a complete 1.5 mm × 1.5 mm square of each surface.

FIGURE 1. Devices investigated. (A) AGV FP7 (silicone base plate), (B) AGV S-2 (polypropylene base plate), (C) BGI BG101-350 (silicone), and (D) MDI S1 (polypropylene). All devices were photographed at the same scale.

FIGURE 2. Typical profilometric measurement. Arrow in the white-light CLSM image (A) indicates the site and direction of measurement of the profile shown in (B). Area, 800 μm × 800 μm. The RMS was calculated for each measured profile.
Protein Adsorption on Implant Surfaces
To rule out the confounding effects of surface chemistry on the observed cell adhesion, we quantified adsorption of collagen on the implant surfaces indirectly by an immunologic approach: The devices, fixed in standard culture dishes, as explained earlier, were incubated with a solution containing 1 mg/mL type I collagen from rat tail (PAN Biotech GmbH, Aidenbach, Germany) on a rocking platform at room temperature overnight. After repeated rinsing with PBS/H11001/0.1% Tween (PBST), the devices were incubated with 1:2000 polyclonal antibody against type I rat collagen (mouse-anti-rat COL1A, sc-59772; Santa Cruz Biotechnology, Heidelberg, Germany) for 2 hours at room temperature. Excess antibody was washed off with PBST and FITC-labeled secondary antibody (goat-anti-mouse; Meridian Life Science Inc., Saco, ME) coupled to protein-G beads (Dynabeads; Invitrogen Dynal, Oslo, Norway) were added at a concentration of 2 × 10⁶ beads per culture dish. After 1 hour of incubation at room temperature, unbound beads were rinsed off by repeated washing with PBST. The number of beads bound to collagen adsorbed to the implant surface was assessed with the same CLSM set-up described earlier. Because of the small size of the beads (2.8 ± 0.2 μm), a higher magnification was used than that used for the cell counts. Thus, we determined the average number of beads per 375 μm × 375 μm of surface area.

Statistical Analysis
All measurements were taken at least in triplicate, and representative images were chosen for this report. GDD surface topography was described qualitatively. Cell adhesion was measured as the mean number of cells per 1.5 mm × 1.5 mm of surface area (± SD), protein adsorption was indirectly quantified as the mean number of antibody-coated beads per 375 μm × 375 μm of surface area (± SD). Quantitative measurements of the surface roughness are expressed as the RMS (± SD) of the surface profiles obtained by white-light CLSM.

RESULTS
Topographic Images
Images obtained by white-light CLSM showed very distinct topographic features of the upper base plate surfaces (Fig. 2). The surface texture of the Ahmed devices appeared to be much rougher due to prominent hill-and-valley structures. In contrast, at the same magnification, both the Baerveldt and Molteno implants showed rather smooth surfaces with only a few irregularities. Some comparatively shallow arced ridges and grooves were visible on the surface of the Molteno base plate (Figs. 4D, 5D). SEM images at the same scale showed
similar surface features (data not shown). At higher magnification, a different order of roughness was seen with SEM, superposed on the larger hill-and-valley structures of the AGVs. The BGI showed some irregularities at this scale, whereas the MDI base plates were homogenous and smooth (Fig. 6).

**Profilometry**

Profilometric measurements of the surface roughness confirmed that the silicone AGV (FP7) showed the greatest roughness with an RMS roughness of $1.5 \pm 0.1 \, \mu m$. Similarly, at $1.3 \pm 0.1 \, \mu m$, the polypropylene base plate (S-2) was rather rough. The BGI was substantially smoother at $0.10 \pm 0.01 \, \mu m$ for the base plate. The MDI showed an even lower surface roughness than the BGI and overall was the smoothest of all devices ($0.07 \pm 0.01 \, \mu m$).

**Tenon Fibroblast Adhesion**

Cell adhesion corresponded very well to surface roughness and was most profound on the base plates of the AGVs at $100 \pm 24$ cells per $1.5 \, \mu m \times 1.5 \, mm$ for the FP7 model and $47 \pm 13$ cells for the S-2 model, respectively ($n = 4$). Fibroblast attachment was considerably less pronounced on the smoother base plates of the BGI ($15 \pm 3$ cells, $n = 4$) and MDI ($5 \pm 1$ cells, $n = 3$). The number of cells corresponded well with the measured roughness ($R^2 = 0.82$; Fig. 7A).

**Collagen Adsorption**

Collagen adsorption did not correlate with surface roughness or cell adhesion. The mean number of beads bound per $375 \, \mu m \times 375 \, \mu m$ surface area were $53 \pm 24$ for the AGV FP7, $145 \pm 37$ for the S-2 model, $107 \pm 27$ for the BGI, and $230 \pm 63$ for the MDI ($n = 3$ for all devices, $R^2 = 0.36$, Fig. 7B). Although there was a marked difference between the base plate materials in the number of beads captured by bound collagen ($75 \pm 19$ for silicone vs. $177 \pm 38$ for polypropylene), an influence of the amount of collagen on cell adhesion was not detected.

**DISCUSSION**

Since the development of the MDI, which introduced the basic concept of connecting the anterior (or posterior) chamber to a base plate via a silicone tube, many different glaucoma drainage implants have been developed. They drain aqueous into an equatorial subconjunctival bleb, inside which a base plate is
intended to ensure that the bleb area is sufficiently large for adequate aqueous resorption. The BGI is similar in basic design to the MDI, but differs in material (the BGI is made of silicone, whereas the base plate of the MDI is made of polypropylene), size, and shape. The AGV features a flow restrictor intended to prevent hypotony and was first introduced with a base plate manufactured from polypropylene (S-2-type). When it was recognized that the rigidity of this material may have been partly responsible for a higher incidence of encapsulation,1,5 the base plate was later replaced by a more flexible model made from silicone, which led to the increased overall success reported in the literature.10–17

Even though these implants have been shown to be successful and safe, with short and intermediate term success and complication rates approximately equal to trabeculectomy,1,16–18 studies of long-term implant survival show a high frequency of failure of IOP control (for review of surgical outcomes, see Schwartz et al.20). Moreover, this failure rate does not seem to be significantly reduced by the use of anti-fibrotic drugs such as mitomycin C.5,6,21

It is generally accepted that final IOP largely depends on the amount of aqueous humor resorbed from the bleb that forms because of aqueous drainage around the base plate. The size of the base plate is directly responsible for the size of the aqueous resorption area and thus correlates inversely with IOP, up to an upper size limit of 550 mm², above which there appears to be no further decrease of IOP.22–24 Histopathologic studies show that resorption is restricted by the formation of a fibrous capsule around the base plate during the course of normal wound healing and that the thickness of the proliferative fibrovascular layer of this capsule directly correlates with final IOP.3

The incidence of implant failure due to excessive fibrotic encapsulation varies considerably from study to study and between the different devices. In many reports, bleb encapsulation or fibrosis were not explicitly mentioned. Since the capsular thickness correlates with IOP, however, the occurrence of a hypertensive phase within approximately 1 month of GDD implantation as well as the increasing need for adjunctive medication over time in some GDD models is likely to be an indication of excessive fibroblast proliferation and ECM deposition.

It is interesting to note that there were marked differences between the incidences of hypertensive phases in the different implant models. While reports of a hypertensive phase in patients receiving an MDI or BGI are only anecdotal (estimated 20%–30%),25–27 high IOP develops within weeks after implanta-

### Table 1. Studies Reporting on Hypertensive Phases after GDD Implantation

<table>
<thead>
<tr>
<th>Study</th>
<th>Device</th>
<th>Patients (n)</th>
<th>Hypertensive Phase (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stewart et al.27</td>
<td>Molteno SP</td>
<td>38</td>
<td>31.6</td>
</tr>
<tr>
<td>Lloyd et al.28</td>
<td>Baerveldt</td>
<td>18</td>
<td>38.9</td>
</tr>
<tr>
<td>Ayyala et al.26</td>
<td>Molteno DP</td>
<td>30</td>
<td>43.5</td>
</tr>
<tr>
<td>Ayyala et al.25</td>
<td>Ahmed</td>
<td>85</td>
<td>82.4</td>
</tr>
<tr>
<td>Susanna29</td>
<td>Ahmed</td>
<td>92</td>
<td>46.8</td>
</tr>
<tr>
<td>Nouri-Mahdavi and Caprioli20</td>
<td>Ahmed</td>
<td>156</td>
<td>56.4</td>
</tr>
<tr>
<td>Wu et al.31</td>
<td>Ahmed</td>
<td>19</td>
<td>63.2</td>
</tr>
<tr>
<td>Hong et al.4</td>
<td>Baerveldt/Molteno</td>
<td>20–30</td>
<td></td>
</tr>
<tr>
<td>Schwartz et al.20</td>
<td>Baerveldt/Molteno</td>
<td>20–30</td>
<td></td>
</tr>
</tbody>
</table>

SP, single plate; DP, double plate.

* Rabbit model.

† Estimates based on indirect evidence from reports without explicit mention of hypertensive phase.

There is evidence that part of this difference between the AGV and nonvalved implants is due to the timing of the first contact between aqueous humor and the surgical wound. It is generally accepted, that growth factors in the aqueous exert fibrogenic effects on the filtering bleb.3 Early hypotony with nonvalved implants is avoided by ligating or occluding the devices with a stent to prevent immediate drainage of aqueous. This configuration has the extra advantage of avoiding early contact between aqueous and the conjunctiva of the newly formed bleb, possibly protecting from excessive exposure to TGF-β and other cytokines. Ligation or stenting of the tube delays aqueous flow through the device until wound healing has passed the inflammatory phase and the hydraulic conductivity of the bleb has decreased enough to avoid hypotony.5 In the AGV, the flow restrictor in the device reduces the incidence of hypotony,5,5,5,59 but still permits immediate drainage of some aqueous, which, when exposed to the subtenon fibroblasts, may enhance the degree of bleb encapsulation. Since the final IOP is largely determined by the rate of aqueous resorption from the filtering bleb and the valve mechanism of the AGV is designed to open at pressures of approximately 10 to 12 mm Hg, it should not in principle contribute to failure to control IOP. However, there have been reports of failure due to valves damaged during the implantation procedure.50–57 In addition, because of the lower incidence of hypotony, the mean final IOP may be slightly higher for AGVs than for nonvalved devices.

Our data suggest that base plate surface topography is also a factor in the clinically observed differences in encapsulation rates. Both AGV models show distinctly rough surfaces with an RMS roughness that is approximately one order of magnitude greater than that of the BGI and MDI (Figs. 4, 6). A possible explanation of the higher rate of hypertensive phase after AGV implantation (both types) is early attachment of tenon fibroblasts to the implant; indeed, in our experimental setup, cells adhered best to the rough surfaces (Fig. 5). Although the differences in macroscopic design and base plate material of the devices used in this study prohibit a valid quantitative comparison, it is evident that there are marked differences in the ability of cells to adhere to the investigated surfaces in vitro. The number of attached cells per area appears to correlate very well with the measured surface roughness in our study (K = 0.82, Fig. 7A).

The effects of surface structure on cell adhesion have been extensively studied with other implant designs, materials, and cell types, and there is a clear correlation between surface roughness and cell adhesion.58–60 Moreover, fibroblast growth is known to be anchorage dependent. Adhesion via integrins greatly enhances growth factor signaling and is a prerequisite for activation, proliferation, and ECM deposition (for a review, see Chiquet et al.41). Hence, initial tenon fibroblast adhesion to the implant surface, with subsequent activation and proliferation, could facilitate the formation of thick fibrovascular tissue and be an explanation for the higher incidence of the hypertensive phase and rapid encapsulation of the AGV.

It is worth noting that in our experiments there appeared to be slightly better adhesion of cells on the silicone surfaces when compared with that on the polypropylene devices of similar roughness (i.e., AGV FP7 versus S-2 at 1.5 and 1.5 μm, and BGI
versus MDI at 0.1 and 0.07 μm). This finding may be indicative of topographic influences other than RMS roughness (e.g., homogeneity of texture or sharp versus rounded edges), but could also be the result of surface chemical effects. Our results do not show a strong correlation between collagen adsorption (as surrogate for surface chemistry) and cell adhesion on the investigated surfaces. However, there is a difference in the mean amount of collagen adsorbed between the base plate materials with more collagen immunologically detected on the polypropylene devices (data not shown). This is in accordance with the observation that polypropylene implants produce a more pronounced inflammatory response in a rabbit model than silicone implants. In our in vitro experiments protein adsorption does not appear to contribute much to cell adhesion, whereas roughness seems to exert the predominant effect.

A limitation of our study is the difficulty in transferring our ex vivo results to the clinical setting. It is not clear whether attachment of cells occurs at the early stages of wound healing after implantation. On clinical exploration of encapsulated blebs, the fully formed fibrous capsule is usually not visibly adherent to the implant in situ, and at the time of intervention, the capsules are typically removed without macroscopically visible adherence to the implant.

An alternative explanation of the increased tendency for encapsulation of rough implants may be stretch-mediated activation of fibroblasts through micromovement of the tenon and conjunctiva on top of the surface of the base plate. It has been shown that fibroblasts react to mechanical stress by increasing the expression of actin stress fibers as well as ECM components. Wilcox and Kadri presented evidence that this mechanism is active in tenon fibroblasts around the GDD, showing that collagen fibers and cells align along the direction of tension caused by sharp edges or bulky base plates. The RhoA/Rock signaling pathway appears to play a prominent role in this response to mechanical stimuli. Pichg W, Welge-Luessen U, Grehn F et al. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239(3):199–207.

Acknowledgments

The authors thank Heinz Duschner and Hermann Götz (Institute for Applied Structure and Microanalysis) for providing access to and technical assistance with the confocal laser scanning microscope.

References

20. Heuer DK, Lloyd MA, Abrams DA, et al. Which is better? One or two—a randomized clinical trial of single-plate versus double-


